[The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].

@article{Machaczka1998TheCO,
  title={[The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].},
  author={Maciej Machaczka and Małgorzata Rucińska and Marcin Jabłoński and Aleksander Bartłomiej Skotnicki},
  journal={Przeglad lekarski},
  year={1998},
  volume={55 7-8},
  pages={407-13}
}
Acute myelogenous leukemia (AML) represents 80% of adult acute leukemias. A standard-dose chemotherapy allows to obtain 52% to 72% of complete remission (CR). A major limitation for success in chemotherapy of AML is dominance of drug-resistant subpopulations of cells. Cytosine-arabinoside (Ara-C) is a basic drug in AML treatment. Myeloblasts resistance to… CONTINUE READING